Aurinia Pharmaceuticals/$AUPH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Primary listing
Employees
130
Headquarters
Edmonton, Canada
Website
AUPH Metrics
BasicAdvanced
$1.9B
26.27
$0.55
1.46
-
Price and volume
Market cap
$1.9B
Beta
1.46
52-week high
$16.20
52-week low
$6.55
Average daily volume
1.8M
Financial strength
Current ratio
5.756
Quick ratio
5.018
Long term debt to equity
16.635
Total debt to equity
21.383
Interest coverage (TTM)
18.31%
Profitability
EBITDA (TTM)
100.551
Gross margin (TTM)
80.16%
Net profit margin (TTM)
29.28%
Operating margin (TTM)
30.51%
Effective tax rate (TTM)
2.26%
Revenue per employee (TTM)
$2,040,000
Management effectiveness
Return on assets (TTM)
9.41%
Return on equity (TTM)
20.65%
Valuation
Price to earnings (TTM)
26.268
Price to revenue (TTM)
7.443
Price to book
5.21
Price to tangible book (TTM)
5.26
Price to free cash flow (TTM)
16.505
Free cash flow yield (TTM)
6.06%
Free cash flow per share (TTM)
0.875
Growth
Revenue change (TTM)
20.62%
Earnings per share change (TTM)
-449.88%
3-year revenue growth (CAGR)
27.25%
10-year revenue growth (CAGR)
101.08%
3-year earnings per share growth (CAGR)
-12.81%
10-year earnings per share growth (CAGR)
-1.83%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
AUPH News
AllArticlesVideos
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Business Wire2 days ago
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Business Wire3 days ago
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.9B as of November 06, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 26.27 as of November 06, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.